MyGenom project begins recruitment in Sabah
The Ministry of Health (MOH) and the Ministry of Science, Technology and Innovation (MOSTI), in a joint statement, said that the initiative, which began in Kota Kinabalu, is being implemented through collaboration between MOH healthcare facilities and public higher education institutions (IPTA).
They said that the collaborative move strengthens grassroots involvement and launches recruitment operations in urban and rural areas in Sabah, where the state, with its unique genetic and ethnic diversity, is given priority in this project.
In this regard, the ministries urged Sabahans, particularly the Bumiputera community, who have been underrepresented in genomic research, to actively participate in the project, enabling them to benefit from advancements in precision medicine and future health policies.
'The MyGenom project is being carried out as a strategic effort to build the nation's genomic assets to strengthen the health system, through data and technology, in line with the aspirations of the Health White Paper and the Malaysia MADANI framework.
'This project is being implemented under the National Biotechnology Policy 2.0 (DBN 2.0), through the Perdana 4 programme, which focuses on the application of genomics technology and targeted therapies to improve public health,' they said.
Under the initiative, MOH is responsible for genomic sampling and public health-related analysis, while MOSTI, through the Malaysia Genome and Vaccine Institute (MGVI) under the National Institutes of Biotechnology Malaysia (NIBM), oversees the genome sequencing process using advanced facilities.
The project is currently in Phase 1, with 3,150 participants recruited from Peninsular Malaysia and Sarawak since August 2024, nearing the total target of 3,600 participants.
'The National Institutes of Health (NIH) and the Institute for Medical Research (IMR) are leading this initiative, focusing on underrepresented communities, including the Bumiputera of Sabah and Sarawak, as well as the Orang Asli,' the ministries said.
As of June 19, 2025, a total of 1,080 genomes have been successfully sequenced in Malaysia, with technical cooperation from MOH. This effort is supported by MOSTI's investment in a high-performance sequencing system, enabling more efficient processing of hundreds of samples while ensuring that the country's genetic data sovereignty is maintained.
Phase 2 will be expanded, with a target of sequencing 10,000 genomes from Malaysians of diverse ethnicities, localities, and backgrounds, a crucial step to avoid bias in understanding diseases and treatment responses.
'This genomic data will be utilised in stages for the management of chronic diseases, such as heart disease, cancer, diabetes, and rare diseases,' they said.-Bernama
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Sun
6 hours ago
- The Sun
Malaysia steps up investment in R&D in quest to become high-tech nation by 2030
KUALA LUMPUR: Malaysia is expanding its investment in research and development (R&D) as part of its push to become a high-technology nation by 2030, said Deputy Science, Technology and Innovation Minister Datuk Mohammad Yusof Apdal. He highlighted that Malaysia's gross expenditure on R&D (GERD) reached 1.01% of gross domestic product in 2022, a notable increase, with more than 51% contributed by the industry sector. 'Looking ahead, we are targeting GERD to reach 2.5% by 2030, in line with our national goal of transforming into a high-technology nation,' Mohammad Yusof said in his speech at the soft launch of the Asean Technology Cooperation and Development Summit 2025 today. He said the mission of the Science, Technology and Innovation Ministry (Mosti) is anchored in a vision to transform Malaysia from a technology user into a technology developer with global market capabilities by 2030. 'We are committed to unlocking value through innovation that is commercially viable, socially inclusive, and globally relevant.' Mohammad Yusuf said the government is accelerating real-world innovation with the National Technology and Innovation Sandbox (NTIS), providing a platform for pre-commercial technologies to be tested and adapted at scale. 'Since its inception, NTIS has supported numerous innovative solutions, focusing on applications ranging from precision drones to AI diagnostics and renewable energy systems.' Additionally, Malaysia is investing in talent as an estimated 600,000 Malaysians will need to be reskilled over the next three to five years due to artificial intelligence and automation. 'Mosti is addressing this challenge through structured training pathways, academic-industry partnerships, and regional innovation exchanges.' Mohammad Yusof said that as chair of Asean, Malaysia is committed to leading efforts that drive regional integration and forward-looking cooperation. 'One of our key priorities is to accelerate innovation and technology-driven development – not only within our borders, but across the wider Asean community.' The soft launch was attended by the embassy of China's science and technology counsellor Dr Zhao Xiangdong and second secretary for science and technology Dr Zhang Tianhang. The Asean Technology Cooperation and Development Summit 2025, organised by Intrinsic SEA, will be held alongside WE2025: Future in Motion, a three-day programme from Nov 25 to 27 organised by Qube Integrated Malaysia Sdn Bhd. The summit, to be held on Nov 25 and 26 at the Malaysia International Trade and Exhibition Centre, Kuala Lumpur, is expected to secure over RM200 million in innovation and investment deals. Themed 'Future in Motion,' it will focus on five pillars – future mobility and smart transportation, future healthcare and digital medicine, future consumer and digital commerce, future building and safety emergency response, and future employment and entrepreneurship. The two-day event is set to convene over 100 companies, more than 50 global investors, and 2,000 innovators and ecosystem leaders from Asean, China, Canada, Australia, the Middle East, Europe and Japan. It will feature a technology exhibition with over 100 booths highlighting innovations across key sectors. The summit is expected to attract more than 50,000 livestream viewers.
The Star
7 hours ago
- The Star
Hepatitis C treatment can be safely shortened
A new clinical trial conducted in Malaysia has found that an eight-week regimen of ravidasvir and sofosbuvir is just as safe and effective as the standard 12-week treatment for chronic hepatitis C. This finding could accelerate efforts to scale up access to treatment in resource-limited settings by reducing treatment duration, costs and system burden. The EASE study (Evaluating Accelerated Shortened treatment for hepatitis C in Asia through real-world Evidence) was led by the Health Ministry (MOH) and conducted across 26 sites nationwide between March 2021 and March 2023. The randomised trial involved 322 patients diagnosed with chronic hepatitis C virus infection, including those with more complex medical profiles. The primary objective was to determine whether an eight-week treatment course using the fixed-dose combination of ravidasvir and sofosbuvir would achieve similar sustained virological response (SVR), compared to the standard 12-week regimen. An SVR refers to the continued absence of the hepatitis C virus in a patient's blood 12 weeks or more after they have completed treatment. It is essentially considered a virological cure for the infection. The study found no significant difference in efficacy between the two durations, with high SVR rates maintained in both arms. Safety profiles were also comparable, with no new adverse effects identified. The results were officially reported by the MOH in January (2025) and presented at the 2025 European Association for the Study of the Liver (EASL) Congress in early May in Amsterdam, the Netherlands. Ravidasvir was co-developed through a public-health partnership involving the MOH, Drugs for Neglected Diseases initiative (DNDi), Pharco Pharmaceuticals (Egypt) and Pharmaniaga Berhad (Malaysia), with key clinical trials conducted in Malaysia and Thailand. The treatment was first registered in Malaysia in 2021 and added to the World Health Organization (WHO) Essential Medicines List in 2023. While hepatitis C continues to affect approximately 50 million people globally, with only about 20% receiving treatment, high drug prices remain a barrier in many countries. A 2023 MOH study estimates 0.4% of the population in Malaysia to have hepatitis C. In line with WHO targets, Malaysia aims to eliminate the disease as a public health threat by 2030.
The Sun
10 hours ago
- The Sun
Malaysia commits to safe nuclear tech at INSO 2025
SUBANG JAYA: Malaysia has reinforced its commitment to the responsible use of nuclear technology at the International Nuclear Science Olympiad (INSO) 2025. Higher Education Deputy Minister Datuk Mustapha Sakmud highlighted the event as a celebration of scientific excellence and international cooperation. He stated that INSO promotes discovery, friendship, and shared ambition in advancing nuclear science. The competition, hosted by Pusat PERMATA@Pintar Negara and UKM, gathered young talents from 14 countries. Mustapha emphasised nuclear science's role in national development, including healthcare and industrial applications. He noted its global importance in tackling climate change, energy security, and public health challenges. The collaborative spirit of INSO aligns with the need for scientists working toward humanity's betterment. Mustapha thanked agencies like MOSTI, IAEA, and the Malaysian Nuclear Agency for supporting the event. He revealed Malaysia's plan to transition to renewable energy, including nuclear power, under the 13th Malaysia Plan. The country aims to develop nuclear power plants within a decade to achieve net-zero emissions by 2050. Efforts are underway to encourage students to pursue nuclear science for a sustainable energy future. UKM's long-standing nuclear education programme since the 1980s made it an ideal co-host for INSO 2025. The closing ceremony honoured medalists and special award winners in various categories. The INSO trophy was handed over to Dr Maya Al-Azri, marking the transition to the next host. – Bernama
